Oklahoma mom is accused of 'child abuse' for TikTok showing her 22lb four-month-old son
Maci Mugele shared a clip of her son Gunner on TikTok last month, with the caption: 'When you have a 100th percentile, off-the-charts four-month-old.'
Viewers were astounded at his size, with many loving his 'chunky rolls' and 'cute' features - but others took aim at the 21-year-old and accused her of 'child abuse' over Gunner's weight.
Mom Maci said: 'He always measured a week or two ahead [when I was pregnant].
'I could just tell that he was pretty big and everybody already told me that my stomach was bigger than average.
'You only have two scans throughout your pregnancy so I went to an ultrasound place and paid for [one] to be done to see how big he was.
'They told me that he was measuring quite large for how far along I was. I think I was 34 weeks when he was measuring at 6lb 3oz.'
Mega bump: Maci said her son 'always measured a week or two ahead' during her pregnancy and everyone told her that her belly 'was bigger than average'
Maci said: 'The doctors said that he's healthy but sometimes people just have big babies. He's big for his height as well so I think that contributes to him being bigger.
'Ever since the second day in the hospital, he has eaten more than the average baby - doctors always told me he was eating a little bit more than the normal baby, which is fine, they said.'
Gunner's in the 100th percentile for his weight and the 90th percentile for his height.
Maci was surprised by some of the negative reaction she got, and didn't see how it could be cruel to feed a hungry baby.
She said: 'It made me upset to realize that there are people like that in this world that feel so comfortable saying these things about a baby.
'That's just so sad to me, and I would never want people to say things about him like that.
'I thought that people would think it was cute if they saw it, but I didn't realize how horrible people can be. I don't know how it's cruel or abusive that I feed him whenever he's hungry.
'I feel like it would be abusive if I didn't feed him when he was hungry and crying.
'Like the doctor said, he's perfectly healthy and has no problem with his weight.'
Some TikTokers were quick to criticize Gunner's size in the comments.
While others defended him as 'cute' and many predicted it's a good indication that he would be tall when he got older.
Not right: It made her upset to see how comfortable people were with their negative comments
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
22 minutes ago
- Reuters
Congressional forecaster says Trump health research cuts would lead to fewer new drugs
WASHINGTON, July 18 (Reuters) - President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on the market, the U.S. Congressional Budget Office said on Friday. The Trump administration's 2026 budget proposal includes deep cuts for scientific research, including $18 billion in cuts from the NIH's funding, a 40% reduction. In a letter responding to a request from congressional Democrats, CBO Director Phillip Swagel said the nonpartisan agency estimates a hypothetical 10% cut in the NIH's funding of preclinical research would reduce the number of drug candidates for phase 1 clinical trials over 30 years, starting with one fewer drug in the first decade, nine in the second, and 20 in the third. "CBO estimated that a reduction in the NIH's funding of external preclinical research would ultimately decrease the number of new drugs coming to market by roughly 4.5 percent, or about 2 drugs per year," the letter said. Preclinical research is the earliest stage of drug development, so the effects of funding cuts take longer to kick in. CBO expects cuts to clinical trials, in which drugs are further along in development, to also reduce the number of new drugs and to take effect sooner, but did not provide an analysis. Congressional Democrats had also asked CBO to analyze the implications of reducing NIH funding by 35%-38% but the office said it had not determined whether historical data could reliably be used to do so. CBO said it was updating its drug development model to address congressional interest in additional budget scenarios. Democrats also asked the CBO to analyze the effects of a nine-month increase in U.S. Food and Drug Administration review times of new drug applications. The Trump administration has carried out mass layoffs at the agency, initially firing 3,500 employees, though some have since been rehired. CBO found such a delay would lead to three fewer drugs entering the market in the first decade, and 10 fewer in both the second and third decades. Delays in reviews would probably affect drug development in additional ways that CBO did not assess, the office said. The Trump administration is proposing a $6.8-billion budget request for the FDA in 2026, representing a cut of around 5.5%from this year.
Daily Mail
24 minutes ago
- Daily Mail
Startling immune hack that makes tumors disappear could unlock a universal cancer vaccine
Scientists may be one step closer to a universal cancer vaccine that could revolutionize how the disease is treated. The vaccine uses mRNA, messenger RNA, the same technology behind the COVID-19 vaccines, which carries instructions for cells to produce specific proteins. However, instead of directing cells to make a protein that triggers an immune response, researchers at the University of Florida used mRNA that acts as a red flag itself, immediately alerting the immune system and prompting a reaction. In their study, mice implanted with human melanoma tumors were treated with the mRNA vaccine alongside immunotherapy drugs, medications designed to harness and boost the immune system, once a week for three weeks. The combination helped immune cells recognize and attack the cancer, leading to tumor shrinkage and, in some cases, complete disappearance. All untreated mice died within 50 days, but among those that received the vaccine and immunotherapy, every mouse survived at least 60 days, and more than half were still alive at day 100 when the experiment ended. The research remains in its early stages and has not yet been tested in humans, but scientists said it offers a promising glimpse into a future where chemotherapy, radiation, and surgery may no longer be necessary in the fight against cancer. Dr Elias Sayor, a pediatric oncologist which led the research, said: 'This paper describes a very unexpected and exciting observation: That even a vaccine not specific to any particular tumor or virus could lead to tumor-specific effects. 'This finding is proof of concept that these vaccines potentially could be commercialized as universal cancer vaccines that might sensitize the immune system against a patient's individual tumor,' she continued. Scientists consider developing a cancer vaccine, targeting one of the leading causes of death, to be a 'holy grail' of medical breakthroughs. There are currently two main approaches in cancer vaccine development, including identifying a common target found in many patients with a particular cancer, or creating a personalized vaccine tailored to an individual's specific tumor. However, the team behind this new research believes their study introduces a promising third approach, one that focuses on stimulating a powerful immune response rather than targeting cancer directly. Dr Duane Mitchell, a neurosurgeon and co-author of the study, explained: 'What we found is by using a vaccine designed not to target cancer specifically, but rather to stimulate a strong immunologic response, we could elicit a very strong anti-cancer reaction. 'This has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine.' Each year, about 104,000 Americans are diagnosed with melanoma, the deadliest form of skin cancer. When caught early, it's often treatable, but if the cancer spreads, the five-year survival rate drops to just 34 percent. In the study, scientists used mRNA derived from mitochondria, the energy-producing structures within cells, which can also trigger a rapid immune response. The researchers tested their new vaccine on several types of cancer in mice, including skin, bone, and brain cancers, and found that in many cases, the tumors shrank or disappeared entirely following treatment. Dr. Elias Sayour, a pediatric oncologist and lead investigator, suggested the vaccine may help activate T cells, immune cells responsible for detecting and destroying threats, which previously failed to respond, prompting them to multiply and attack cancerous cells. Dr. Duane Mitchell added: 'It could potentially be a universal way of waking up a patient's own immune response to cancer. And that would be profound if generalizable to human studies.' While the vaccine is still likely years away from clinical use, the team says they are actively working to advance it into human trials. The research was published in the journal Nature Biomedical Engineering.
Reuters
30 minutes ago
- Reuters
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says
July 18 (Reuters) - The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics (SRPT.O), opens new tab to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told Reuters on Friday. Sarepta's stock tumbled over 40% to $12.81, its lowest level in more than nine years, after being briefly halted. A company spokesperson said the drugmaker has yet to receive a formal request. The agency's scrutiny of Sarepta has sharpened since the deaths of two teenage boys earlier this year who had received Elevidys, a gene therapy approved in the United States to treat a muscle-wasting condition called Duchenne muscular dystrophy. Earlier on Friday, Sarepta disclosed the death of a third patient - a 51-year-old man with limb-girdle muscular dystrophy who had received its experimental gene therapy SRP-9004. Like the two teenagers, he died from acute liver failure and was non-ambulatory, meaning unable to walk independently. In June, Sarepta stopped shipments of the therapy to such patients. Wall Street analysts have said the third death could amplify patient hesitancy to use Elevidys, given both the therapies use the same delivery vehicle known as adeno-associated virus vector. The company is in the process of changing its label for Elevidys, and the FDA will see the change through, the source told Reuters on Friday. Earlier in the day, FDA Commissioner Marty Makary told Bloomberg News in an interview that he was "taking a hard look" at whether a gene therapy from Sarepta should remain on the market. On an investor call on Friday, Sarepta faced pointed questions from analysts over why it had not disclosed the recent patient death earlier in the week. CEO Doug Ingram said the matter was "neither material, nor central" to Wednesday's update that had focused on the company's restructuring. "This event occurred in a trial that was otherwise completed with all dosing," said Ingram, adding that the decision to not proceed with the study was made independently of the patient's death. The company also said liver issues were not a new safety signal in the study, which is part of its now-halted limb-girdle muscular dystrophy (LGMD) gene therapy programs. On Wednesday, Sarepta had announced 500 layoffs as well as cuts to its LGMD programs, citing financial reasons. It had not mentioned the patient death then, despite analyst inquiries about safety. Sarepta reiterated the financial basis of its decision on Friday's investor call, but some analysts, including those at BMO Capital Markets, warned it could damage management credibility. At least two analysts asked whether other deaths had occurred in Sarepta's gene therapy programs. The company said it was not aware of any beyond the three that were disclosed. "We are, historically, a very transparent organization. If there was a change in the risk profile of Elevidys, we would first and foremost, share with physicians and patients, and then, of course, we would share it with investors," Ingram said.
